# Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

> **NCT01784562** · — · NO_LONGER_AVAILABLE · sponsor: **Bayer**

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Adempas (Riociguat, BAY63-2521)

## Key facts

- **NCT ID:** NCT01784562
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01784562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01784562, "Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01784562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*